2/3/4 and NRAS exons 2/3/4 were amplified in two PCRs using Phusion HS II (Thermo Fisher Scientific Inc., Wilmington, USA) and adapters for hybridization and sequencing (grey) as well as barcodes for demultiplexing (blue) were attached ( Supplementary Fig. 1A ). All primers are shown in Supplementary Table 1 .
Amplicons were purified and multiplex-sequenced with a 500-cycle single indexed (8 nucleotides) paired-end run on a MiSeq Illumina sequencer. Overlapping paired reads were merged using FLASH (v1.2.6), non-overlapping reads excluded and Usearch (v6.0.307) was employed to dereplicate and cluster the merged reads. All sequences observed more then 30 times were aligned with reference EGFR, KRAS and NRAS exon sequences ( Supplementary Table 2 ). Deviations from the germline sequence were classified as "mutations" if not identical to a known polymorphism and if present in >1% of reads.
For NGS on circulating tumor DNA (ctDNA), EGFR exon 12 was amplified as shown in Supplementary Figure 1B , KRAS exon 2/3/4 and NRAS exon 2/3/4 amplified in two PCRs as mentioned above (tumor tissue), using primers shown in Supplementary   Table 1 . Amplicons were purified and multiplex-sequenced with a 300-cycle single indexed (6 nucleotides) paired-end run. Data analysis was performed as above.
Supplementary Figure 1: PCR amplification of EGFR, KRAS and NRAS exons for targeted next generation sequencing.
A: In the "tumor tissue" patient cohort, EGFR exons 7-13, KRAS exons 2/3/4 and NRAS exons 2/3/4 (green) were amplified and Illumina-specific sequences for hybridization and sequencing (grey) as well as patient-specific barcodes (blue) were attached by a two-step PCR approach. B: In the "liquid biopsy" patient cohort, exon 12 was amplified for the detection of the G465R and the S492R mutation by a three-step PCR approach. G = position G465; S = position S492. KRAS and NRAS exons 2/3/4 were amplified in a two-step PCR system analogous to the "tumor tissue" patient cohort shown in Suppl. Figure 
